Literature DB >> 8652823

Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins.

P E Harris1, A Maffei, A I Colovai, J Kinne, S Tugulea, N Suciu-Foca.   

Abstract

Human myeloid progenitor cells temporarily express HLA class II molecules during the differentiation pathway to granulocytes and macrophages. The significance of major histocompatibility complex (MHC) class II molecules at this stage of development is unknown. As a first stop of inquiry into their function, we have characterized the profile of major self-peptides bound to the HLA-DR molecules expressed by KG-1 cells, a line that shares many of the phenotypic characteristics of colony-forming unit-granulocyte-macrophage progenitors. Searches of protein data bases showed that all matching peptides bound to the HLA-DR molecules of KG-1 cells corresponded to intracellular, rather than exogenous or transmembrane, precursor proteins. Because the absence of a conventional self-peptide repertoire could be related to altered trafficking of class II molecules, the biosynthesis of HLA-DR and the invariant chain proteins was determined. The MHC class II associated invariant chain protein is synthesized normally in KG-1 cells, but processed fragments of invariant chain, class II-associated invariant chain peptides (CLIPs), occupy the antigen-binding groove of KG-1 class II molecules at a much lower frequency compared with that of mature antigen-presenting cells. Low CLIP occupancy of HLA-DR is a characteristic shared by KG-1 cells, normal CD34+ progenitor cells, and HLA-DR+ breast carcinoma cells. The unusual profile of MHC class II bound peptides and the low level of CLIP bound to HLA-DR suggest that the antigen-processing pathway of KG-1 is different from that characterized in professional antigen-presenting cells and that exogenous antigen-processing may be a developmentally acquired characteristic in the myeloid lineage.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8652823

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains.

Authors:  K Frauwirth; N Shastri
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

Review 2.  Presentation of cytosolic antigens via MHC class II molecules.

Authors:  Delu Zhou; Janice S Blum
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 3.  Autophagy in innate and adaptive immunity against intracellular pathogens.

Authors:  Dorothee Schmid; Jörn Dengjel; Oliver Schoor; Stefan Stevanovic; Christian Münz
Journal:  J Mol Med (Berl)       Date:  2006-01-28       Impact factor: 4.599

4.  Definition of the peptide binding motif within DRB1*1401 restricted epitopes by peptide competition and structural modeling.

Authors:  Eddie A James; Antonis K Moustakas; Deanna Berger; Laurie Huston; George K Papadopoulos; William W Kwok
Journal:  Mol Immunol       Date:  2008-02-13       Impact factor: 4.407

5.  Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.

Authors:  Marvin M van Luijn; Martine E D Chamuleau; James A Thompson; Suzanne Ostrand-Rosenberg; Theresia M Westers; Yuri Souwer; Gert J Ossenkoppele; S Marieke van Ham; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

6.  Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.

Authors:  Marvin M van Luijn; Martine E D Chamuleau; Maaike E Ressing; Emmanuel J Wiertz; Suzanne Ostrand-Rosenberg; Yuri Souwer; Adri Zevenbergen; Gert J Ossenkoppele; Arjan A van de Loosdrecht; S Marieke van Ham
Journal:  Cancer Immunol Immunother       Date:  2010-09-05       Impact factor: 6.968

7.  Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.

Authors:  Marvin M van Luijn; Arjan A van de Loosdrecht; Margit H Lampen; Peter A van Veelen; Adri Zevenbergen; Michel G D Kester; Arnoud H de Ru; Gert J Ossenkoppele; Thorbald van Hall; S Marieke van Ham
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.